Compounds > lutetium
Page last updated: 2024-08-22

lutetium and Ovarian Neoplasms

lutetium has been researched along with Ovarian Neoplasms in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (14.29)18.2507
2000's5 (35.71)29.6817
2010's7 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abrahmsen, L; Ekblad, C; Frejd, FY; Jonsson, A; Lindborg, M; Lundqvist, H; Orlova, A; Rosik, D; Tolmachev, V1
Adam, MJ; Lewis, JS; Orvig, C; Price, EW; Zeglis, BM1
Cohrs, S; Dorrer, H; Fischer, E; Grünberg, J; Köster, U; Lindenblatt, D; Schibli, R; Türler, A; Zhernosekov, K1
Aerts, A; Baatout, S; Caveliers, V; D'Huyvetter, M; De Raeve, H; Devoogdt, N; Impens, N; Lahoutte, T; Muyldermans, S; Vincke, C; Xavier, C1
Cohrs, S; Fischer, E; Grünberg, J; Hohn, A; Jeger, S; Novak-Hofer, I; Schibli, R; Waldner-Knogler, K; Zimmermann, K1
Alvarez, R; Grizzle, W; LoBuglio, A; Meredith, R; Partridge, E; You, Z1
Abbas, N; Brevik, EM; Bruland, ØS; Dahle, J1
Andersson, K; Carlsson, J; Gedda, L; Persson, M; Sandström, M; Tolmachev, V1
Grünberg, J; Knogler, K; Novak-Hofer, I; Schubiger, PA; Zimmermann, K1
Carlsson, J; Gedda, L; Lundqvist, H; Malmström, PU; Nordgren, H; Persson, M; Tolmachev, V1
Andersson, K; Baastrup, B; Carlsson, J; Galli, J; Lundqvist, H; Nilsson, FY; Orlova, A; Pehrson, R; Rosik, D; Sandström, M; Tolmachev, V; Wennborg, A1
Alvarez, RD; Grizzle, WE; Khazaeli, MB; Liu, T; LoBuglio, AF; Meredith, RF; Partridge, EE; Plott, G; Russell, CD; Schlom, J; Wheeler, RH1
Alvarez, RD; Austin, M; Grizzle, WE; Khazaeli, MB; Kilgore, L; Liu, T; LoBuglio, AF; Meredith, RF; Partridge, EE; Plott, G; Russell, CD; Schlom, J1
Alvarez, RD; Austin, JM; Grizzle, WE; Khazaeli, MB; Kilgore, LC; Lin, CY; LoBuglio, AF; Macey, DJ; Meredith, RF; Partridge, EE; Schlom, J1

Trials

3 trial(s) available for lutetium and Ovarian Neoplasms

ArticleYear
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1996, Volume: 37, Issue:9

    Topics: Adenocarcinoma; Aged; Antibodies, Neoplasm; Dose-Response Relationship, Radiation; Female; Humans; Lutetium; Middle Aged; Ovarian Neoplasms; Radioimmunodetection; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon

1996
Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.
    Gynecologic oncology, 1997, Volume: 65, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal; Arthralgia; Bone Marrow; Disease Progression; Dose-Response Relationship, Radiation; Female; Humans; Injections, Intraperitoneal; Lutetium; Middle Aged; Ovarian Neoplasms; Platelet Count; Radioimmunotherapy; Radioisotopes

1997
Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
    Cancer biotherapy & radiopharmaceuticals, 2001, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Injections, Intraperitoneal; Interferon Type I; Lutetium; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Recombinant Proteins; Treatment Outcome

2001

Other Studies

11 other study(ies) available for lutetium and Ovarian Neoplasms

ArticleYear
Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:6

    Topics: Albumins; Animals; Binding Sites; Cell Line, Tumor; Female; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Mice; Ovarian Neoplasms; Protein Structure, Tertiary; Protein Transport; Radioisotopes; Radiometry; Receptor, ErbB-2; Recombinant Fusion Proteins; Substrate Specificity; Tissue Distribution

2013
H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu.
    Dalton transactions (Cambridge, England : 2003), 2014, Jan-07, Volume: 43, Issue:1

    Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Chelating Agents; Female; Humans; Indium; Isotope Labeling; Lutetium; Mice; Mice, Nude; Organophosphorus Compounds; Ovarian Neoplasms; Ovary; Positron-Emission Tomography; Radioisotopes; Trastuzumab; Zirconium

2014
Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
    European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Female; Humans; Lutetium; Mice; Neural Cell Adhesion Molecule L1; Ovarian Neoplasms; Radioimmunotherapy; Radioisotopes; Terbium; Tissue Distribution; Tomography, Emission-Computed, Single-Photon

2014
Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
    Theranostics, 2014, Volume: 4, Issue:7

    Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Female; Humans; Lutetium; Male; Mice; Mice, Nude; Ovarian Neoplasms; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rats; Rats, Wistar; Receptor, ErbB-2; Single-Chain Antibodies; Trastuzumab

2014
L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer.
    International journal of cancer, 2012, Jun-01, Volume: 130, Issue:11

    Topics: Animals; Antibodies, Monoclonal; Female; Humans; Lutetium; Mice; Mice, Inbred BALB C; Neural Cell Adhesion Molecule L1; Ovarian Neoplasms; Radioimmunotherapy; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Xenograft Model Antitumor Assays

2012
Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
    Cancer biotherapy & radiopharmaceuticals, 2012, Volume: 27, Issue:1

    Topics: Adult; Aged; Animals; Antibodies, Neoplasm; Disease-Free Survival; Female; Humans; Immunotoxins; Infusions, Parenteral; Lutetium; Mice; Middle Aged; Ovarian Neoplasms; Prognosis; Radioimmunotherapy; Radiopharmaceuticals; Yttrium Radioisotopes

2012
Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
    Nuclear medicine communications, 2012, Volume: 33, Issue:8

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Female; Lutetium; Mice; Neoplasms, Experimental; Organometallic Compounds; Ovarian Neoplasms; Platelet Count; Radioisotopes; Receptor, ErbB-2; Rituximab; Tissue Distribution; Trastuzumab; Treatment Outcome

2012
[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.
    European journal of nuclear medicine and molecular imaging, 2005, Volume: 32, Issue:12

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Lutetium; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Organ Specificity; Ovarian Neoplasms; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptor, ErbB-2; Staining and Labeling; Tissue Distribution

2005
Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.
    Nuclear medicine and biology, 2006, Volume: 33, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Cell Line; Chelating Agents; Drug Evaluation, Preclinical; Female; Glycosylation; Heterocyclic Compounds, 1-Ring; Humans; Liver; Lutetium; Metabolic Clearance Rate; Mice; Mice, Nude; Neural Cell Adhesion Molecule L1; Ovarian Neoplasms; Radioisotopes; Radiopharmaceuticals

2006
[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.
    Cancer research, 2007, Jan-01, Volume: 67, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Beta Particles; Female; Humans; Immunotoxins; Lutetium; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Radioisotopes; Tissue Distribution; Xenograft Model Antitumor Assays

2007
Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Cancer research, 2007, Mar-15, Volume: 67, Issue:6

    Topics: Animals; Antibody Specificity; Cell Line, Tumor; Female; Humans; Immunotoxins; Lutetium; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Radioisotopes; Receptor, ErbB-2; Recombinant Fusion Proteins; Tissue Distribution; Xenograft Model Antitumor Assays

2007